Bowel biopsy the only available method to confirm celiac disease Drugs Market
An autoimmune condition called
celiac disease primarily affects the small intestine. It is primarily seen in
people who are predisposed to gluten genetically. Diarrhea, abdominal
distention, appetite loss, failure to grow normally in children, and
occasionally loss of lymphocytes are just a few of the symptoms of celiac
disease.
Clinical trials for the celiac
disease medications are still ongoing. As the symptoms of celiac disease can be
mistaken for those of other bowel disorders, it can be difficult to diagnose it
in its early stages. The disease is screened using a variety of subtle and
specific blood tests, such as anti-tissue transglutaminase antibodies. Since
there is no known or specific treatment for the condition, if the test results
are positive, the patient is asked to have a small bowel biopsy to confirm the
diagnosis. Large-scale R&D initiatives currently under way are anticipated
to open the door for more accurate and sophisticated diagnostic tools as well
as novel medications, positioning the global
celiac disease drugs market on a high growth trajectory.
In the United States, celiac
disease affects 1 in 133 healthy individuals and is thought to affect 1 in 56
individuals who experience related symptoms. One in 22 and one in 39 people,
respectively, have celiac disease in first or second degree relatives. Post-clinical
trial approval, this creates extremely lucrative growth opportunities for
market participants in celiac disease medications. In the years following drug
approval, Asia Pacific is likely to experience rapid growth rates, with China
and India accounting for the majority of industry revenue. The development of
the global market for drugs for celiac disease is, however, significantly
constrained by strict regulatory frameworks for drug approval.
Comments
Post a Comment